Thermo Fisher Scientific finalized the $7.2 billion acquisition of 95.3% in ordinary shares of Patheon, a contract development and manufacturing organization that provides drug development services and delivery solutions. The purchase will enhance Thermo Fisher's CDMO capabilities in the fields of bioproduction technology and clinical trial services, said Marc Casper, Thermo Fisher's president and CEO.
Thermo Fisher announces completion of $7.2B Patheon purchase
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.